June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Anti-Scg3 Therapy for Corneal Neovascularization
Author Affiliations & Notes
  • Remya Ammassam Veettil
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Hong Tian
    Everglades Biopharma, LLC, Texas, United States
  • Stephen C Pflugfelder
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Wei Li
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Douglas Koch
    Ophthalmology, Baylor College of Medicine, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Remya Ammassam Veettil None; Hong Tian Everglades Biopharma, LLC, Code C (Consultant/Contractor), Everglades Biopharma, LLC, Code E (Employment), Everglades Biopharma, LLC, Code I (Personal Financial Interest); Stephen Pflugfelder Abbvie, Dompe, Kala, Kowa, Code C (Consultant/Contractor), Dompe, Code F (Financial Support), Immuneyez, Code O (Owner); Wei Li Everglades Biopharma, LLC, Code I (Personal Financial Interest), University of Miami, Code P (Patent); Douglas Koch Acufocus, Alcon, Carl Zeiss Meditec, Bausch & Lomb, Johnson & Johnson Vision, PerfectLens, Code C (Consultant/Contractor)
  • Footnotes
    Support  The SRB Charitable Corporation; NIH R41EY027665; R43EY032827; P30EY002520; RPB; Knights Templar Eye Foundation
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1730. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Remya Ammassam Veettil, Hong Tian, Stephen C Pflugfelder, Wei Li, Douglas Koch; Anti-Scg3 Therapy for Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1730.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Currently, there is no approved drug therapy for corneal neovascularization (KNV). Anti-angiogenic drugs against vascular endothelial growth factor (VEGF) have been used off-label to treat KNV but with potential side effects on corneal epithelium and nerves. Secretogranin III (Scg3) was recently discovered as a disease-restricted angiogenic factor, and Scg3-neutralizing antibodies have been developed for disease-targeted therapy of other ocular angiogenic diseases with significant safety advantages. The purpose of this study is to determine and compare the efficacy of anti-Scg3 and anti-VEGF in mouse model of KNV.

Methods : Alkali burn was performed on C57BL/6J mice to induced KNV. Mice were treated topically or subconjunctivally with anti-Scg3 humanized antibody (hAb), the anti-VEGF drug aflibercept, or phosphate buffered saline (PBS). To evaluate treatment efficacy, corneal images were taken on Day 5, 7, and 10 post alkali burn and analyzed for KNV score and total length of new vessels. Corneas were harvested on Day 10, immunostained for blood vessels using anti-CD31 mAb or for lymph vessels using anti-LYVE-1 mAb, imaged by confocal microscopy, and analyzed by ImageJ software.

Results : Anti-Scg3 hAb significantly reduced total length of alkali burn-induced new corneal vessels by 78%. Aflibercept had similar efficacy to inhibit total length of new vessels by 60%. Immunostaining of corneas confirmed that anti-Scg3 hAb markedly reduced CD31 + corneal blood vessels and LYVE-1+ lymph vessels in alkali-burned corneas with similar efficacy to that of aflibercept treatment. In contrast, PBS control had no detectable therapeutic activity. No significant difference between limbal blood vessel number and density were observed between healthy mice and anti-Scg3-treated mice.

Conclusions : These findings suggested that anti-Scg3 hAb and aflibercept significantly inhibit KNV with similar efficacy. In light of the disease-targeting property of anti-Scg3 hAb to selectively inhibit pathological angiogenesis with undetectable adverse effects on healthy vessels, neurons and epithelium, our findings warrant further investigation to compare the efficacy and safety of anti-Scg3 and aflibercept for anti-angiogenic therapy of KNV.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.